Larvol Veri

My recent searches

No previous search


PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	durvalumab Sensitive: A1 - Approval AstraZeneca Press Release - 1 day Sensitive: A1 - Approval AstraZeneca Press Release - 1 day
No biomarker No biomarker	Urothelial Cancer Urothelial Cancer	padeliporfin Sensitive: B - Late Trials Cision - 1 day Sensitive: B - Late Trials Cision - 1 day
ALK positive ALK positive	Non-Hodgkin’s Lymphoma NHL	crizotinib Sensitive: A1 - Approval FDA - 2 days Sensitive: A1 - Approval FDA - 2 days
No biomarker No biomarker	Chronic Lymphocytic Leukemia CLL	rituximab + ibrutinib Sensitive: A1 - Approval Cision - 3 days Sensitive: A1 - Approval Cision - 3 days
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	tislelizumab Sensitive: A1 - Approval BeiGene Press Release - 3 days Sensitive: A1 - Approval BeiGene Press Release - 3 days
No biomarker No biomarker	Sarcoma Sarcoma	INBRX-109 Sensitive: B - Late Trials Inhibrx Press Release - 3 days Sensitive: B - Late Trials Inhibrx Press Release - 3 days
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval J Cancer Res Clin Oncol - 4 days Sensitive: A1 - Approval J Cancer Res Clin Oncol - 4 days
HER-2 positive HER-2 positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: A1 - Approval J Oncol Pharm Pract - 4 days Sensitive: A1 - Approval J Oncol Pharm Pract - 4 days
No biomarker No biomarker	Acute Myelogenous Leukemia AML	azacitidine oral Sensitive: A1 - Approval Cision - 4 days Sensitive: A1 - Approval Cision - 4 days
TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	nivolumab Sensitive: A2 - Guideline IASLC-WCLC 2020 - 4 days Sensitive: A2 - Guideline IASLC-WCLC 2020 - 4 days
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	icotinib Sensitive: B - Late Trials IASLC-WCLC 2021 - 4 days Sensitive: B - Late Trials IASLC-WCLC 2021 - 4 days
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	icotinib Sensitive: B - Late Trials IASLC-WCLC 2021 - 4 days Sensitive: B - Late Trials IASLC-WCLC 2021 - 4 days
EGFR mutation EGFR mutation	Lung Cancer Lung Cancer	Tyrosine kinase inhib Sensitive: B - Late Trials IASLC-WCLC 2020 - 4 days Sensitive: B - Late Trials IASLC-WCLC 2020 - 4 days
MLL3 mutation + TMB-H MLL3 mutation + TMB-H	Non Small Cell Lung Cancer NSCLC	PD-L1 inhib Sensitive: B - Late Trials IASLC-WCLC 2020 - 4 days Sensitive: B - Late Trials IASLC-WCLC 2020 - 4 days
MLL3 mutation + TMB-H MLL3 mutation + TMB-H	Non Small Cell Lung Cancer NSCLC	PD1 inhib + CTLA4 inhib Sensitive: B - Late Trials IASLC-WCLC 2020 - 4 days Sensitive: B - Late Trials IASLC-WCLC 2020 - 4 days
RET fusion RET fusion	Lung Cancer Lung Cancer	lenvatinib Sensitive: B - Late Trials IASLC-WCLC 2021 - 4 days Sensitive: B - Late Trials IASLC-WCLC 2021 - 4 days
KMT2D mutation + TMB-H KMT2D mutation + TMB-H	Non Small Cell Lung Cancer NSCLC	PD-L1 inhib Sensitive: B - Late Trials IASLC-WCLC 2020 - 4 days Sensitive: B - Late Trials IASLC-WCLC 2020 - 4 days
KRAS G12C KRAS G12C	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	Immunotherapy Sensitive: B - Late Trials IASLC-WCLC 2020 - 4 days Sensitive: B - Late Trials IASLC-WCLC 2020 - 4 days
KMT2D mutation + TMB-H KMT2D mutation + TMB-H	Non Small Cell Lung Cancer NSCLC	PD1 inhib + CTLA4 inhib Sensitive: B - Late Trials IASLC-WCLC 2020 - 4 days Sensitive: B - Late Trials IASLC-WCLC 2020 - 4 days
BRAF V600E BRAF V600E	Glioblastoma GBM	trametinib + dabrafenib Sensitive: C1 - Off-label Curr Probl Cancer - 4 days Sensitive: C1 - Off-label Curr Probl Cancer - 4 days
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	olmutinib Sensitive: C2 – Inclusion Criteria Cancer - 4 days Sensitive: C2 – Inclusion Criteria Cancer - 4 days
TMB-H + PD-L1 overexpression TMB-H + PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials IASLC-WCLC 2021 - 4 days Sensitive: C3 – Early Trials IASLC-WCLC 2021 - 4 days
TNB-H TNB-H	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials IASLC-WCLC 2021 - 4 days Sensitive: C3 – Early Trials IASLC-WCLC 2021 - 4 days
PD-L1 overexpression PD-L1 overexpression	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	GB226 Sensitive: C3 – Early Trials J Hematol Oncol - 4 days Sensitive: C3 – Early Trials J Hematol Oncol - 4 days
ALK rearrangement ALK rearrangement	Lung Adenocarcinoma LUAD	Tyrosine kinase inhib Sensitive: C3 – Early Trials IASLC-WCLC 2020 - 4 days Sensitive: C3 – Early Trials IASLC-WCLC 2020 - 4 days
HER-2 amplification HER-2 amplification	Non Small Cell Lung Cancer NSCLC	SHR-1258 + rivoceranib Sensitive: C3 – Early Trials IASLC-WCLC 2021 - 4 days Sensitive: C3 – Early Trials IASLC-WCLC 2021 - 4 days
STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	APG-115 Sensitive: C3 – Early Trials IASLC-WCLC 2021 - 4 days Sensitive: C3 – Early Trials IASLC-WCLC 2021 - 4 days
HER-2 G766V HER-2 G766V	Non Small Cell Lung Cancer NSCLC	lapatinib + SHR-1258 Sensitive: C3 – Early Trials IASLC-WCLC 2021 - 4 days Sensitive: C3 – Early Trials IASLC-WCLC 2021 - 4 days
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	Tyrosine kinase inhib Sensitive: C3 – Early Trials IASLC-WCLC 2020 - 4 days Sensitive: C3 – Early Trials IASLC-WCLC 2020 - 4 days
EGFR mutation + KRAS mutation EGFR mutation + KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	Tyrosine kinase inhib Sensitive: C3 – Early Trials IASLC-WCLC 2020 - 4 days Sensitive: C3 – Early Trials IASLC-WCLC 2020 - 4 days
HER-2 A775_G776insYVMA HER-2 A775_G776insYVMA	Non Small Cell Lung Cancer NSCLC	SHR-1258 + rivoceranib Sensitive: C3 – Early Trials IASLC-WCLC 2021 - 4 days Sensitive: C3 – Early Trials IASLC-WCLC 2021 - 4 days
PRDX1 exon 5 - NTRK1 exon 12 fusion PRDX1 exon 5 - NTRK1 exon 12 fusion	Lung Adenocarcinoma LUAD	Trk inhib Sensitive: C4 – Case Studies IASLC-WCLC 2020 - 4 days Sensitive: C4 – Case Studies IASLC-WCLC 2020 - 4 days
EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	Tyrosine kinase inhib Resistant: C3 – Early Trials IASLC-WCLC 2021 - 4 days Resistant: C3 – Early Trials IASLC-WCLC 2021 - 4 days
EGFR overexpression EGFR overexpression	Osteosarcoma Osteosarcoma	gemcitabine Resistant: D – Preclinical Acta Biochim Biophys Sin (Shanghai) - 4 days Resistant: D – Preclinical Acta Biochim Biophys Sin (Shanghai) - 4 days
No biomarker No biomarker	Urothelial Cancer Urothelial Cancer	avelumab Sensitive: A1 - Approval Cision - 5 days Sensitive: A1 - Approval Cision - 5 days
MSI-H/dMMR MSI-H/dMMR	Colorectal Cancer CRC	pembrolizumab Sensitive: A1 - Approval ASCO-GI 2021 - 5 days Sensitive: A1 - Approval ASCO-GI 2021 - 5 days
MSI-H/dMMR MSI-H/dMMR	Colorectal Cancer CRC	nivolumab + ipilimumab Sensitive: A1 - Approval ASCO-GI 2021 - 5 days Sensitive: A1 - Approval ASCO-GI 2021 - 5 days
RET fusion RET fusion	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	pralsetinib Sensitive: A1 - Approval ASCO-GI 2021 - 5 days Sensitive: A1 - Approval ASCO-GI 2021 - 5 days
BRCA2 mutation BRCA2 mutation	Pancreatic Cancer Pancreatic Cancer	olaparib Sensitive: A1 - Approval ASCO-GI 2021 - 5 days Sensitive: A1 - Approval ASCO-GI 2021 - 5 days
BRCA1 mutation BRCA1 mutation	Pancreatic Cancer Pancreatic Cancer	olaparib Sensitive: A1 - Approval ASCO-GI 2021 - 5 days Sensitive: A1 - Approval ASCO-GI 2021 - 5 days
IDH1 mutation IDH1 mutation	Cholangiocarcinoma Cholangiocarcinoma	ivosidenib Sensitive: A2 - Guideline ASCO-GI 2021 - 5 days Sensitive: A2 - Guideline ASCO-GI 2021 - 5 days
HER-2 amplification HER-2 amplification	Colorectal Cancer CRC	trastuzumab + pertuzumab Sensitive: A2 - Guideline ASCO-GI 2021 - 5 days Sensitive: A2 - Guideline ASCO-GI 2021 - 5 days
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	gefitinib Sensitive: B - Late Trials BMC Cancer - 5 days Sensitive: B - Late Trials BMC Cancer - 5 days
BRAF mutation BRAF mutation	Colorectal Cancer CRC	ziv-aflibercept IV Sensitive: B - Late Trials ASCO-GI 2021 - 5 days Sensitive: B - Late Trials ASCO-GI 2021 - 5 days
BRAF mutation BRAF mutation	Colorectal Cancer CRC	bevacizumab Sensitive: B - Late Trials ASCO-GI 2021 - 5 days Sensitive: B - Late Trials ASCO-GI 2021 - 5 days
No biomarker No biomarker	Merkel Cell Carcinoma Merkel Cell Carcinoma	AST-008 Sensitive: B - Late Trials Exicure Press Release - 5 days Sensitive: B - Late Trials Exicure Press Release - 5 days
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	afatinib Sensitive: C1 - Off-label BMC Cancer - 5 days Sensitive: C1 - Off-label BMC Cancer - 5 days
RET fusion RET fusion	Pancreatic Cancer Pancreatic Cancer	pralsetinib Sensitive: C1 - Off-label ASCO-GI 2021 - 5 days Sensitive: C1 - Off-label ASCO-GI 2021 - 5 days
RET fusion RET fusion	Cholangiocarcinoma Cholangiocarcinoma	pralsetinib Sensitive: C1 - Off-label ASCO-GI 2021 - 5 days Sensitive: C1 - Off-label ASCO-GI 2021 - 5 days
HER-2 overexpression HER-2 overexpression	Gastric Cancer Gastric Cancer	ASLAN001 Sensitive: C2 – Inclusion Criteria ASCO-GI 2021 - 5 days Sensitive: C2 – Inclusion Criteria ASCO-GI 2021 - 5 days